Clinical Trial

Extended Release Protein Dosing

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall goal of this study is to determine the minimum dose required to elicit measurable elevation of plasma essential amino acid levels 12 hours after consuming VitaKey's extended release protein technology. The results of this study will be used to set a dose for future protein clinical studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-16.
Status change: Recruiting → Active, Not Recruiting 2026-03-20
Trial Details
NCT Number NCT07313436
Lead Sponsor VitaKey Inc.
Collaborators: United States Department of Defense
Conditions Nutrition
Enrollment 21 participants
Start Date 2025-11-17
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-24